Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Khetbadei L H Hadem

Khetbadei L H Hadem

Indian Council of Agricultural Research for North Eastern Hill Region, India

Title: Activity guided characterization of active compounds of Aristolochia tagala with potential role as anticancer drugs

Biography

Biography: Khetbadei L H Hadem

Abstract


Traditional healthcare system is widely practiced in rural areas of India. Aristolochia tagala is one among the plants used by several traditional practitioners in different herbal preparations for treatment of cancer and other pathophysiological conditions. Our previous studies have reported the chemo-preventive potential of crude aqueous-methanol extract of A. tagala against DEN-induced hepatocellular carcinoma (HCC) in BALB/c mice. The identification of biologically active compounds can give an insight into the mechanism of action of A. tagala as a potential anticancer drug. In this study, the crude methanol extract of A. tagala was fractionated by column chromatography. The fractions were further validated for their antioxidant property by their ability to scavenge free radicals such as superoxide, nitric oxide and ABTS radical cation. The preliminary cytotoxic effect of the plant as well as the fractions against cancerous cells was carried in human cervical carcinoma HeLa cells by colorimetric MTT metabolic activity assay. The fraction with λ max 323, 290, 258 nm showed the highest scavenging activity. The fraction also showed a more efficient cytotoxic effect against HeLa cells. The 50% inhibition of proliferation by the fractionated compounds was at lower dose compared to crude extract. Flow cytometric analysis of cell cycle and apoptotic events induced by fractions and crude extract is being carried out. Purification and characterization of above fraction with anticancer compounds are underway.